

ACURA PHARMACEUTICALS, INC  
Form 8-K  
June 23, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D. C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934**

**June 22, 2005**  
Date of Report (Date of earliest event reported)

---

**ACURA PHARMACEUTICALS, INC.**  
(Exact Name of Registrant as Specified in Charter)

---

**State of New York**  
(State of Other Jurisdiction of  
Incorporation)

**1-10113**  
(Commission File Number)

**11-0853640**  
(I.R.S. Employer Identification  
Number)

**616 N. North Court, Suite 120**  
**Palatine, Illinois 60067**  
(Address of principal executive offices) (Zip Code)

**(847) 705-7709**  
(Registrant's telephone number, including are code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))



**Item 8.01 Other Events**

On June 22, 2005, Acura Pharmaceuticals, Inc. (the "Company") issued a press release announcing completion of bridge financing in the principal amount of \$1 million pursuant to the terms of that certain Loan Agreement by and among the Company and Essex Woodlands Health Venture V, L.P., Care Capital Investments II, L.P., Care Capital Offshore Investments II, L.P., Galen Partners III, L.P., Galen Partners International III, L.P., and Galen Employee Fund III, L.P., dated June 22, 2005. A copy of the Company's press release is attached as Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits.**

**Exhibit  
Number**

**Description**

99.1	Press Release dated June 22, 2005 Announcing Completion of \$1 Million Bridge Financing.
------	--

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter A. Clemens

---

Peter A. Clemens  
Vice President & Chief Financial Officer

Date: June 22, 2005

**EXHIBIT INDEX**

Exhibit

Number Description

99.1 Press Release dated June 22, 2005 Announcing Completion of \$1 Million Bridge Financing.

---